Nothing Special   »   [go: up one dir, main page]

DK1037886T3 - Triazine angiogenesis inhibitors - Google Patents

Triazine angiogenesis inhibitors

Info

Publication number
DK1037886T3
DK1037886T3 DK98963082T DK98963082T DK1037886T3 DK 1037886 T3 DK1037886 T3 DK 1037886T3 DK 98963082 T DK98963082 T DK 98963082T DK 98963082 T DK98963082 T DK 98963082T DK 1037886 T3 DK1037886 T3 DK 1037886T3
Authority
DK
Denmark
Prior art keywords
triazine
angiogenesis inhibitors
compounds
angiogenesis
exacerbated
Prior art date
Application number
DK98963082T
Other languages
Danish (da)
Inventor
Jack Henkin
Donald J Davidson
George S Sheppard
Keith W Woods
Richard W Mccroskey
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/209,396 external-priority patent/US6150362A/en
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK1037886T3 publication Critical patent/DK1037886T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds having Formula (I) or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.
DK98963082T 1997-12-12 1998-12-11 Triazine angiogenesis inhibitors DK1037886T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99011997A 1997-12-12 1997-12-12
US09/209,396 US6150362A (en) 1997-12-12 1998-12-10 Triazine angiogenesis inhibitors
PCT/US1998/026369 WO1999031088A1 (en) 1997-12-12 1998-12-11 Triazine angiogenesis inhibitors

Publications (1)

Publication Number Publication Date
DK1037886T3 true DK1037886T3 (en) 2003-08-25

Family

ID=26904132

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98963082T DK1037886T3 (en) 1997-12-12 1998-12-11 Triazine angiogenesis inhibitors

Country Status (20)

Country Link
EP (1) EP1037886B1 (en)
JP (1) JP2002542144A (en)
KR (1) KR20010032998A (en)
CN (1) CN1290264A (en)
AT (1) ATE239012T1 (en)
AU (1) AU1818599A (en)
BG (1) BG104584A (en)
BR (1) BR9813468A (en)
CA (1) CA2313776A1 (en)
DE (1) DE69814151T2 (en)
DK (1) DK1037886T3 (en)
ES (1) ES2198088T3 (en)
HU (1) HUP0202076A3 (en)
IL (1) IL136339A0 (en)
NO (1) NO20003018L (en)
PL (1) PL344861A1 (en)
PT (1) PT1037886E (en)
SK (1) SK8662000A3 (en)
TR (1) TR200001690T2 (en)
WO (1) WO1999031088A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
FR2804113B1 (en) * 2000-01-26 2004-06-18 Lipha ANIMATED DIHYDRO-1,3,5-TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
AR029489A1 (en) 2000-03-10 2003-07-02 Euro Celtique Sa PIRIDINES, PYRIMIDINES, PIRAZINAS, TRIAZINES REPLACED BY ARILO, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AU2002247402A1 (en) * 2001-03-23 2002-10-08 Chugai Seiyaku Kabushiki Kaisha Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
AR037233A1 (en) 2001-09-07 2004-11-03 Euro Celtique Sa PIRIDINAS ARIL REPLACED, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT
AR036873A1 (en) 2001-09-07 2004-10-13 Euro Celtique Sa PIRIDINAS ARIL REPLACED A, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
JP2005511509A (en) * 2001-09-21 2005-04-28 レディ ユーエス セラピューティクス インコーポレイテッド Methods and compositions for novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
AU2002342018A1 (en) 2001-10-12 2003-04-28 New York University Trisubstituted triazines compounds with antitubulin activity
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003245669A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
US7592451B2 (en) 2005-06-23 2009-09-22 New York University Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments
FR2896161B1 (en) * 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si USE OF TRIAZINE DERIVATIVES FOR MANUFACTURING A MEDICAMENT HAVING A HEALING OR ANGIOGENIC EFFECT.
KR100761869B1 (en) * 2006-07-07 2007-10-04 김현기 Triazine derivative compound and composition for treating cancer containing them
DE102007054416A1 (en) * 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Process for the preparation of 3,6-dihydro-1,3,5-triazine derivatives for the treatment of diseases associated with insulin resistance syndrome
DK3216793T3 (en) * 2008-05-23 2019-05-06 Wyeth Llc TRIAZINE COMPOUNDS AS P13-KINASE AND MTOR INHIBITORS
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN106632000B (en) * 2016-12-19 2019-04-26 湖北工业大学 Diaryl ketone compound application in preparation of anti-tumor drugs
ES2929994T3 (en) 2018-06-06 2022-12-05 Poxel Sa Treatment methods of subjects suffering from diabetes with chronic kidney disease
BR112020025112A2 (en) 2018-06-14 2021-03-23 Poxel film-coated tablet and process for making the film-coated tablet
CN111686113B (en) * 2019-03-15 2022-12-30 北京大学 Sonic Hedgehog inhibitor and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2358856C3 (en) * 1973-11-26 1981-05-21 Basf Ag, 6700 Ludwigshafen Process for stabilizing aqueous formaldehyde solutions
DE2919496A1 (en) * 1979-05-15 1980-12-04 Degussa NEW BISGUANAMINE
US4555532A (en) * 1983-10-14 1985-11-26 Hitachi, Ltd. Epoxy resin composition
WO1992011247A1 (en) * 1990-12-20 1992-07-09 Nippon Shinyaku Co., Ltd. Anticancer composition and compound
JPH04300874A (en) * 1991-03-29 1992-10-23 Tsumura & Co New 2,4-diamino-1,3,5-triazine derivative
JPH04300832A (en) * 1991-03-29 1992-10-23 Tsumura & Co Leukotriene antagonistic agent containing 2,4-diamino-1,3,5-triazine derivative as active ingredient
TW328955B (en) * 1993-05-14 1998-04-01 Cytec Tech Corp Process for preparing bis- or tris-carbamate functional 1,3,5-triazines, substantially halogen contamination free crosslinker compositions and new bis-or tris-carbamate functional 1,3,5-triazines
DE4423138A1 (en) * 1994-07-01 1996-01-04 Hoechst Ag Elastic one-component epoxy resin system with high storage stability

Also Published As

Publication number Publication date
PL344861A1 (en) 2001-11-19
AU1818599A (en) 1999-07-05
ATE239012T1 (en) 2003-05-15
EP1037886B1 (en) 2003-05-02
DE69814151D1 (en) 2003-06-05
SK8662000A3 (en) 2001-01-18
HUP0202076A3 (en) 2003-12-29
EP1037886A1 (en) 2000-09-27
PT1037886E (en) 2003-09-30
IL136339A0 (en) 2001-05-20
BG104584A (en) 2001-01-31
BR9813468A (en) 2001-11-13
TR200001690T2 (en) 2001-05-21
ES2198088T3 (en) 2004-01-16
HUP0202076A2 (en) 2002-11-28
DE69814151T2 (en) 2004-03-25
JP2002542144A (en) 2002-12-10
NO20003018L (en) 2000-08-04
WO1999031088A1 (en) 1999-06-24
CA2313776A1 (en) 1999-06-24
CN1290264A (en) 2001-04-04
NO20003018D0 (en) 2000-06-13
KR20010032998A (en) 2001-04-25

Similar Documents

Publication Publication Date Title
ATE239012T1 (en) TRIAZINE ANGIOGENESIS INHIBITORS
BG106585A (en) Kinase inhibitors as therapeutic agents
DE60114994D1 (en) PLATELET ADP RECEPTOR INHIBITORS
ATE273305T1 (en) THROMBIN INHIBITORS
JO2372B1 (en) Prodrugs of 4-phenyl-pyridine derivatives
CY1112024T1 (en) ADP HARMONIZATION HOLDER SUSPENSIONS
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE60045426D1 (en) Phenyl-benzyl-ketone
DE60002714D1 (en) SUBSTITUTED AZAOXINDOL DERIVATIVES
IS2125B (en) Cells-suppressing inflammatory-destroying and immunosuppressive compounds
DE69716810D1 (en) 2,3-disubstituted-(5,6) -heteroarylkondensierte-pyrimidin-4-one
CO5261493A1 (en) PROCEDURE AND COMPOUNDS FOR THE INHIBITION OF MRP1
ATE297904T1 (en) HALO-ALKOXYCARBONYL COMPOUNDS
DE69933885D1 (en) TRIPHENYLBUTEN DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CY1105977T1 (en) ANTI-ANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND AMPHIBLISTROIDOPATHY
TR200102514T2 (en) Method for COPD treatment
ATE277018T1 (en) 3,4-DIHYDROCINOLINE DERIVATIVES AS NITROGEN MONOXIDE SYNTHASE (NOS) INHIBITORS
AR013802A1 (en) TRIAZINE ANGIOGENESIS INHIBITORS
SI1077694T1 (en) Aryl nitrone therapeutics for the treatment of inflammatory bowel disease